Bindu Kanapuru

8PUBLICATIONS
56CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersData mining and knowledge discoveryMolecular medicineMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 01, 2026
FDA Approval Summary: Epcoritamab with Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma.

|Aug 27, 2026
Concordance Between Claims-Based and Electronic Health Record-Based Comorbidity Measures: An Application Using Linked Data.

|Mar 18, 2026
Building Capacity for Research on Cancer, Older Adults, and Under-Represented Populations: Methods and Lessons Learned From the Development of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center-Medicare Database.

Tsung-Ying Lee, Eberechukwu Onukwugha, Abree Johnson

|Jun 04, 2025
FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class-Exposed, Relapsed or Refractory Multiple Myeloma.

Poornima Sharma, Xue Lin, Zhenzhen Xu

|Oct 16, 2024
FDA Approval Summary: Teclistamab-A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple Myeloma.

Andrea C Baines, Bindu Kanapuru, Jay Zhao

|May 07, 2024
FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma.

Kavita Natrajan, Megha Kaushal, Bindu George

Pageof 2

Frequent Collaborators

5 joint publications

Marc R Theoret

4 joint publications

Nicole J Gormley

2 joint publications

Andrea C Baines

2 joint publications

Lola A Fashoyin-Aje